Literature DB >> 19556308

The CD70-CD27 interaction during the stimulation with dendritic cells promotes naive CD4(+) T cells to develop into T cells producing a broad array of immunostimulatory cytokines in humans.

Mutsumi Hashimoto-Okada1, Toshio Kitawaki, Norimitsu Kadowaki, Satoshi Iwata, Chikao Morimoto, Toshiyuki Hori, Takashi Uchiyama.   

Abstract

CD70 expressed on dendritic cells (DCs) has been shown to play a critical role in inducing effective CD8(+) T cell responses and a T(h)1 response in mice. However, it has not been extensively examined whether human primary DCs express CD70 and whether the CD70-CD27 interaction promotes naive CD4(+) T cells to acquire the ability to produce effector cytokines during the DC-T cell interaction in humans. Here, we show that human myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells stimulated with CD40 ligand together with pro-inflammatory cytokines or Toll-like receptor ligands express CD70. Thymic stromal lymphopoietin plus prostaglandin E(2) also induced CD70 on mDCs. Naive CD4(+) T cells stimulated with DCs but not with anti-CD3/CD28 microbeads expressed CD70. Stimulation with CD70 together with anti-CD3/CD28 microbeads imparted the ability to produce T(h)1 (IFN-gamma), T(h)2 (IL-4, IL-5, IL-13) cytokines, IL-2 and tumor necrosis factor-alpha to naive CD4(+) T cells. The production of IFN-gamma was associated with the induction of T-bet. Naive CD4(+) T cells stimulated with mDCs acquired an enhanced ability to produce a broad array of immunostimulatory cytokines in a CD70-dependent manner. These data suggest that human CD70 expressed on mDCs and activated T cells transmits a 'basal level' signal, rather than a 'polarizing' signal, to naive CD4(+) T cells, in that CD70 promotes the development of CD4(+) T cells that produce a variety of effector cytokines including both T(h)1 and T(h)2 types, thus contributing to the enhancement of a broad spectrum of immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19556308     DOI: 10.1093/intimm/dxp056

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro.

Authors:  Jianping Huang; Qiong J Wang; Shicheng Yang; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

2.  Optimal stimulation for CD70 induction on human monocyte-derived dendritic cells and the importance of CD70 in naive CD4(+) T-cell differentiation.

Authors:  Kazue Arimoto-Miyamoto; Norimitsu Kadowaki; Toshio Kitawaki; Satoshi Iwata; Chikao Morimoto; Takashi Uchiyama
Journal:  Immunology       Date:  2010-02-26       Impact factor: 7.397

3.  Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenza.

Authors:  Jianping Lin; Suryanarayan Somanathan; Soumitra Roy; Roberto Calcedo; James M Wilson
Journal:  Vaccine       Date:  2010-06-29       Impact factor: 3.641

4.  15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level.

Authors:  Luciano Castiello; David F Stroncek; Michael W Finn; Ena Wang; Francesco M Marincola; Carol Clayberger; Alan M Krensky; Marianna Sabatino
Journal:  J Transl Med       Date:  2011-04-18       Impact factor: 5.531

5.  Expression of the immune regulation antigen CD70 in osteosarcoma.

Authors:  Jens Hw Pahl; Susy J Santos; Marieke L Kuijjer; Gerharda H Boerman; Laurens Gl Sand; Karoly Szuhai; Annemarie Cleton-Jansen; R Maarten Egeler; Judith Vmg Boveé; Marco W Schilham; Arjan C Lankester
Journal:  Cancer Cell Int       Date:  2015-03-18       Impact factor: 5.722

Review 6.  Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.

Authors:  Sebastian Chrétien; Ioannis Zerdes; Jonas Bergh; Alexios Matikas; Theodoros Foukakis
Journal:  Cancers (Basel)       Date:  2019-05-05       Impact factor: 6.639

7.  Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.

Authors:  Edwin Bremer
Journal:  ISRN Oncol       Date:  2013-06-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.